Customer [Domain] Customer [Domain] Inventory, Work in Process, Gross Inventory, Work in Process, Gross Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Percentage of employee vested contribution Defined Contribution Plan, Employees Contribution, Vested Percentage Percentage vested of employee's contributions to defined contribution plan Leasehold improvements Leasehold Improvements [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net loss Net loss Net Income (Loss) Attributable to Parent Operating lease, ROU Assets Operating Lease, Right-of-Use Asset Undesignated preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Income Statement Location [Axis] Income Statement Location [Axis] Range Statistical Measurement [Domain] Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Lease liabilities Increase (decrease) in lease liabilities Increase (decrease) in lease liabilities Forfeited or expired (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Additional paid-in capital Additional Paid in Capital, Common Stock Forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Boehringer Collaboration and License Agreement Boehringer Ingelheim International GmbH Collaboration And License Agreement [Member] Boehringer Ingelheim International GmbH Collaboration And License Agreement Weighted average lease term (in years) Operating Lease, Weighted Average Remaining Lease Term NIAID National Institute of Allergy and Infectious Diseases [Member] Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies. Operating lease liabilities Deferred Tax Assets, Operating Lease Liabilities Deferred Tax Assets, Operating Lease Liabilities Other non current assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Non-refundable upfront payment, net of tax withholding Nonrefundable Upfront Fees, Net Of Tax Withholding Nonrefundable Upfront Fees, Net Of Tax Withholding Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Retirement Benefits [Abstract] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Estimated Useful Lives Property Plant And Equipment Estimated Useful Life Table [Table Text Block] Property plant and equipment estimated useful life. Available-for-sale Debt Securities, Available-for-sale [Table Text Block] Interest Income, Other Interest Income, Other SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Additions Charged to Expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Subsequent Event Type [Domain] Subsequent Event Type [Domain] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Organization, Consolidation and Presentation of Financial Statements [Abstract] McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC [Member] McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC [Member] McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC Variable lease cost Variable Lease, Cost Net deferred income tax asset/(liability) Deferred Tax Assets, Net Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Anti-dilutive stock options Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Research and development Research and Development Expense [Member] Sale of Stock [Axis] Sale of Stock [Axis] Subsequent Events [Abstract] Subsequent Events [Abstract] Net deferred income tax assets Deferred Tax Assets, Net of Valuation Allowance Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Collaboration and Other Agreements Collaboration And License Agreements Disclosure [Text Block] The entire disclosure for collaboration and license agreements. Award Type [Domain] Award Type [Domain] Local Phone Number Local Phone Number Assets Assets [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Vested and expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Non-refundable upfront payment Non-refundable upfront payment Initial fee received from collaboration or license agreement. Federal U.S. net operating loss carryforward Deferred Tax Assets, Operating Loss Carryforwards, Domestic Granted (in shares) Awards granted in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Percentage of significant accounts receivable Concentration Risk, Percentage Property, Equipment and Software Property, Plant and Equipment, Policy [Policy Text Block] Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares) Beginning Balance (in shares) Ending Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Accumulated Deficit Retained Earnings [Member] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Term of agreement (in years) Collaboration And License Agreement, Term Collaboration And License Agreement, Term Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Proceeds from stock option exercises and ESPP purchases Proceeds from Stock Options Exercised And ESPP Purchases Proceeds from Stock Options Exercised And ESPP Purchases Common stock maximum amount available for issuance Common Stock, Maximum Amount Available For Issuance Common Stock, Maximum Amount Available For Issuance Accounts receivable Increase (Decrease) in Accounts Receivable Deferred income tax adjustments Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments. Capital Expenditures Incurred but Not yet Paid Capital Expenditures Incurred but Not yet Paid Right-of-use assets modified in exchange for operating lease obligation Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Components of the Company's Deferred Income Tax Assets (Liabilities) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Indefinite Indefinite [Member] Indefinite Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Commitments and Contingencies Disclosure [Abstract] Tax Period [Domain] Tax Period [Domain] Number of operating segments Number of Operating Segments Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Number of product candidates to develop Number Of Product Candidates Number Of Product Candidates Sublease income Sublease Income Potential development and regulatory milestone payments Potential Development and Regulatory Milestone Payments Under Agreement Potential Development and Regulatory Milestone Payments Under Agreement Beginning Balance (in shares) Ending Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Increases/(decreases) for prior year tax positions Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] At The Market Offering At The Market Offering [Member] At The Market Offering [Member] Prepaid expenses and other current assets Prepaid Expense, Current Imab Imab [Member] Imab Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Tax withholding Non-refundable Payment, Tax Withholding Non-refundable Payment, Tax Withholding SEC Schedule, 12-09, Reserve, Inventory SEC Schedule, 12-09, Reserve, Inventory [Member] Share-based compensation, number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Operating lease payments Operating Lease, Payments Other non-cash items Other Noncash Income (Expense) Depreciation Deferred Tax Liabilities, Property, Plant and Equipment Research and Development Costs, Including Clinical Trial Accruals/Expenses Research and Development Expense, Policy [Policy Text Block] Offering period Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Estimated variable consideration Revenue, Information Used To Assess Variable Consideration, Amount Revenue, Information Used To Assess Variable Consideration, Amount Entity Voluntary Filers Entity Voluntary Filers Fair value of shares vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Diluted net loss per common share (in usd per share) Income (Loss) from Continuing Operations, Per Diluted Share Revenue from collaborative agreements Revenue From Collaborative Agreements [Member] Revenue From Collaborative Agreements Zai Lab Clinical Supply Agreements Zai Lab Clinical Supply Agreements [Member] Zai Lab Clinical Supply Agreements Plan Name [Axis] Plan Name [Axis] Assets [Abstract] Assets, Fair Value Disclosure [Abstract] Total assets measured at fair value Assets, Fair Value Disclosure Quoted Prices in Active Markets for Identical Assets, Level 1 Fair Value, Inputs, Level 1 [Member] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Potential milestone payment to third parties for intellectual property under agreement Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement Income Tax Disclosure [Abstract] State taxes (net of federal benefit) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Entity Small Business Entity Small Business Orphan drug credit, net Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount Increases for current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Total liabilities and stockholders' equity Liabilities and Equity Investments, Debt and Equity Securities [Abstract] Operating lease ROU assets Deferred Tax Liabilities, Operating Lease Right Of Use Assets Deferred Tax Liabilities, Operating Lease Right Of Use Assets Tax Year 2025 To 2037 Tax Year 2025 To 2037 [Member] Tax Year 2025 To 2037 Deferred revenue, current Contract with Customer, Liability, Current Incyte MGA012 Clinical Services Incyte Commercial Supply Agreement [Member] Incyte Commercial Supply Agreement Scenario [Axis] Scenario [Axis] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five Proceeds from sales and maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Development milestones Development Milestones, Amount Development Milestones, Amount I-Mab Biopharma Collaboration And License Agreement Clinical Supply I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member] I-Mab Biopharma Collaboration And License Agreement Clinical Supply Concentration Risk [Line Items] Concentration Risk [Line Items] Liabilities and stockholders' equity Liabilities and Equity [Abstract] Gross unrecognized tax benefits Unrecognized Tax Benefits that Would Impact Effective Tax Rate ASD Healthcare and Oncology Supply [Member] ASD Healthcare and Oncology Supply [Member] ASD Healthcare and Oncology Supply Auditor Information [Abstract] Auditor Information Amounts recognized Development milestones recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Accounts payable Increase (Decrease) in Accounts Payable Potential milestone payments and royalties on product sales Potential Milestone Payments and Royalties On Product Sales Potential Milestone Payments and Royalties On Product Sales SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Incyte MGA012 Supply Agreement Incyte Clinical Supply Agreement [Member] Incyte Clinical Supply Agreement Operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Entity Interactive Data Current Entity Interactive Data Current Minimum Minimum [Member] 2018 Zai Lab Collaboration And License Agreement 2018 Zai Lab Collaboration And License Agreement [Member] 2018 Zai Lab Collaboration And License Agreement Organization and Nature of Operations Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] 2016 Employee Stock Purchase Plan Two Thousand Sixteen Employee Stock Purchase Plan [Member] Two Thousand Sixteen Employee Stock Purchase Plan [Member] Undesignated Preferred Stock Undesignated Preferred Stock [Member] Undesignated Preferred Stock [Member] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Undesignated preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized One Time Millstone Credit One Time Millstone Credit One Time Millstone Credit Beginning balance Ending balance Unrecognized Tax Benefits Gross deferred income tax assets Deferred Tax Assets, Gross Income Tax Authority [Domain] Income Tax Authority [Domain] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Entity Address, State or Province Entity Address, State or Province Incyte Corporation (Incyte) Incyte Corporation [Member] Incyte Corporation [Member] Revenues, Net Of Tax Withholding Revenues, Net Of Tax Withholding Revenues, Net Of Tax Withholding Current liabilities: Liabilities, Current [Abstract] RevenuesFromGrantsMember RevenuesFromGrantsMember Issuance of common stock, net of offering costs Stock Issued During Period, Value, New Issues Revenue Recognition Revenue [Policy Text Block] Selling, general and administrative General and Administrative Expense Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stock-based Compensation Share-based Payment Arrangement [Text Block] Inventory, Net Inventory Disclosure [Text Block] Leases Lessee, Leases [Policy Text Block] Eligible age to participate in plan Employees Eligible Age To Participate In Benefit Plan Refers to minimum eligible age of employee to participate in benefit plan. Accounting Policies [Abstract] Accounting Policies [Abstract] Weighted-average remaining contractual term, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Accumulated other comprehensive income (loss) AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax Issuance of common stock, net of offering costs (in shares) Number of shares issued or sold (in shares) Stock Issued During Period, Shares, New Issues Total lease liabilities Operating Lease, Liability Increased number of shares authorized (in shares) Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase Share based compensation arrangement by share based payment award number of shares authorized after increase. Document Transition Report Document Transition Report Common stock, 0.01 par value -- 125,000,000 shares authorized, 61,307,428 and 56,244,771 shares outstanding at December 31, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Unrecognized compensation expense recognition period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Beginning Balance (in dollars per share) Ending Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Basis of Presentation and Principles of Consolidation Basis of Accounting, Policy [Policy Text Block] Subsequent Event [Table] Subsequent Event [Table] Leases Lessee, Operating Leases [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag I-Mab I-Mab Biopharma [Member] I-Mab Biopharma Schedule of Employee Stock Options Award Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Zai Lab Limited (Zai Lab) Zai Lab Limited [Member] Zai Lab Limited Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Auditor Name Auditor Name Cover [Abstract] Total costs and expenses Costs and Expenses Class of Stock [Axis] Class of Stock [Axis] Cash, Cash Equivalents and Marketable Securities Cash and Cash Equivalents, Policy [Policy Text Block] Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Income Tax Authority [Axis] Income Tax Authority [Axis] Proceeds of stock sale Sale of Stock, Consideration Received on Transaction Financial Instrument [Axis] Financial Instrument [Axis] Accrued expenses and other current liabilities Accrued Liabilities, Current Stock warrants (in shares) Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares Remaining portion of net operating losses Operating Loss Carryforwards Not Subject To Limitation Operating loss carryforwards not subject to limitation. Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Common Stock Common Stock [Member] Transaction price Collaborative Agreement Transaction Price Collaborative Agreement Transaction Price Loss from operations Operating Income (Loss) Defined contribution plan, employer discretionary contribution amount Defined Contribution Plan, Employer Discretionary Contribution Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Lease liabilities Operating Lease, Liability, Current Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Stock plan related activity Stock Issued During Period Value Stock Plan Activity Value of shares issued due to stock plan related activity. Document Fiscal Year Focus Document Fiscal Year Focus Property, Plant and Equipment [Abstract] Share-based compensation Share-based Payment Arrangement, Noncash Expense Additional Paid-In Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation expense Depreciation Revenue from government agreements Revenue From Government Agreements [Member] Revenue From Government Agreements Consideration received common stock warrant exercise price (in usd per share) Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-sale Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Equity-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount Other income Other Nonoperating Income (Expense) Purchases of property, equipment and software Payments to Acquire Property, Plant, and Equipment Deferred revenue Deferred Tax Assets, Deferred Income Maximum Maximum [Member] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Total potential value Total potential value of agreement Refers to total potential value under agreement. 2021 Zai Lab Agreements 2021 Zai Lab Agreements [Member] 2021 Zai Lab Agreements Award Type [Axis] Award Type [Axis] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Aggregate intrinsic value, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Total stockholders' equity Balance Balance Stockholders' Equity Attributable to Parent Undesignated preferred stock, shares issued (in shares) Preferred Stock, Shares Issued City Area Code City Area Code Schedule Of Supplemental Balance Sheet Information, Operating Leases Schedule Of Supplemental Balance Sheet Information, Operating Leases [Table Text Block] Schedule Of Supplemental Balance Sheet Information, Operating Leases Aggregate intrinsic value, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Entity Address, City or Town Entity Address, City or Town Collaboration and License Agreements [Abstract] Collaboration and License Agreements [Abstract] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Estimated Reimbursement for Research and Development t Estimated Reimbursement for Research and Development t Estimated Reimbursement for Research and Development t U.S. Federal and State Domestic Tax Authority and State and Local Jurisdiction [Member] [Member] Domestic Tax Authority and State and Local Jurisdiction [Member] [Member] Estimated useful lives Property, Plant and Equipment, Useful Life Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Non-cash operating and investing activities Noncash Investing and Financing Items [Abstract] Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Software Software and Software Development Costs [Member] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Measurement Frequency [Domain] Measurement Frequency [Domain] Provision for federal or state income taxes Current Income Tax Expense (Benefit) Potential commercial milestone payments Potential Commercial Milestone Payments Under Agreement Potential Commercial Milestone Payments Under Agreement Accumulated deficit Retained Earnings (Accumulated Deficit) Income Tax Examination [Line Items] Income Tax Examination [Line Items] Options granted, maximum term Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Restricted Stock Units Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Entity Filer Category Entity Filer Category Gross deferred income tax liabilities Deferred Tax Liabilities, Gross Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Potential proceeds from royalties percent Proceeds from Royalties, Percent Proceeds from Royalties, Percent U.S Treasury securities U.S. Treasury securities US Treasury Securities [Member] Income Statement [Abstract] Concentration Risk [Table] Concentration Risk [Table] Entity Registrant Name Entity Registrant Name Inventory Disclosure [Abstract] Asset Class [Domain] Asset Class [Domain] Net operating losses limited for use utilized on an annual basis Operating Loss Carryforwards Annual Limitation Amount Amount of net operating loss which are limited for use, utilized on a annual basis. Equity Incentive Plan 2003 Equity Incentive Plan 2003 [Member] Equity Incentive Plan 2003 Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Cash proceeds from exercise of stock options Proceeds from Stock Options Exercised Income tax expense/(benefit) Income Tax Expense (Benefit) Forfeited or expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Entitled milestone payments Entitled Milestone Payments Under Agreement Entitled Milestone Payments Under Agreement Antidilutive Securities [Axis] Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Sale of Stock [Domain] Sale of Stock [Domain] Total lease payments Lessee, Operating Lease, Liability, to be Paid Accounts receivable Accounts Receivable [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Inventory, net Inventory, Net Revenues, tax withholding Revenues, Tax Withholding Revenues, Tax Withholding Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Incyte MGA012 Agreement Incyte MGA012 Agreement [Member] Incyte MGA012 Agreement Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Undesignated preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Entity Public Float Entity Public Float Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Total unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Sales revenue, net Revenue Benchmark [Member] Weighted-average grant-date fair value of options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Prepaid expenditures Deferred Tax Liabilities, Prepaid Expenses Common stock, shares issued (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Common stock purchased by employees (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Laboratory and office equipment Laboratory and Office Equipment [Member] A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine. Deferred income tax assets: Components of Deferred Tax Assets [Abstract] Motor vehicles Vehicles [Member] Statement [Line Items] Statement [Line Items] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Marketable securities Investments Investments U.S. Federal Government Domestic Tax Authority [Member] Securities Fair Value Debt Securities, Available-for-sale Counterparty Name [Domain] Counterparty Name [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Provention PRV3279 Provention PRV3279 [Member] Provention PRV3279 Tax Period [Axis] Tax Period [Axis] Percent of fair market value to purchase shares Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Significant Other Observable Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Research credit, net Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Deferred revenue, noncurrent Contract with Customer, Liability, Noncurrent Valuation allowance Deferred Tax Assets, Valuation Allowance Auditor Location Auditor Location Stock options and RSUs Stock Options And Restricted Stock Units [Member] Stock Options And Restricted Stock Units Janssen Biotech Inc. Janssen Biotech Inc [Member] Counterparty in collaboration agreement Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Customer [Axis] Customer [Axis] Employee Benefit Plan Retirement Benefits [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Asset Class [Axis] Asset Class [Axis] Document Annual Report Document Annual Report Forecast Forecast [Member] Schedule of Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Deferred revenue, net of current portion Deferred Revenue, Noncurrent Title of 12(b) Security Title of 12(b) Security Proceeds from issuance of common stock, net of offering costs Proceeds from Issuance of Common Stock Total assets Assets Stock plan related activity (in shares) Stock Issued During Period Shares Stock Plan Activity Number of shares issued due to stock plan related activity. Deferred income tax liabilities: Components of Deferred Tax Liabilities [Abstract] Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Document Type Document Type Research and development Research and Development Expense Product and Service [Domain] Product and Service [Domain] Lease renewal term (in years) Lessee, Operating Lease, Renewal Term Asset Purchase Agreement Asset Purchase Agreement [Member] Asset Acquisition Agreement Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Premium received on stock purchase Premium received on stock purchase Amount by which purchase price exceeds fair value for common stock purchased by collaborator. Zai Lab Agreement Zai Labs Collaboration And License Agreement [Member] Zai Labs Collaboration And License Agreement Measurement Frequency [Axis] Measurement Frequency [Axis] Net Cash Provided by (Used in) Operating Activities, Total Net Cash Provided by (Used in) Operating Activities US Federal tax credits carry forward Tax Credit Carryforward, Amount Furniture Furniture and Fixtures [Member] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Lease, Cost Lease, Cost [Table Text Block] Subsequent Event [Line Items] Subsequent Event [Line Items] Basic weighted average number of common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Sale of common stock (in dollars per share) Sale of Stock, Price Per Share Product Product [Member] Subsequent Event Subsequent Events [Text Block] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Deferred revenue Contract with Customer, Liability Unrealized gain on investments Unrealized Gain (Loss) on Investments Zai Lab Agreement, TRIDENT molecule Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member] Zai Labs Collaboration And License Agreement, TRIDENT molecule Net Cash Provided by (Used in) Financing Activities, Total Net Cash Provided by (Used in) Financing Activities Orphan drug credit, net Deferred Tax Assets, Tax Credit Carryforwards, Other Unrecognized interest or penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Basic net loss per common share (in usd per share) Income (Loss) from Continuing Operations, Per Basic Share Schedule of RSU Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Corporate debt securities Corporate debt securities Corporate Debt Securities [Member] Reconciliation of Reported Estimated Income Tax Benefit Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Accounts payable Accounts Payable, Current Concentration Risk Type [Axis] Concentration Risk Type [Axis] Depreciation and amortization Depreciation, Depletion and Amortization Net operating loss for limited use Operating Loss Carryforwards Limitations On Use Amount Amount of net operating loss carryforward, which are limited for use over the range of years. Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Inventory Increase (Decrease) in Inventories Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Zai Lab Agreement, Margetuximab Zai Labs Collaboration And License Agreement, Margetuximab [Member] Zai Labs Collaboration And License Agreement, Margetuximab Financial Instruments [Domain] Financial Instruments [Domain] Cost of product sales Cost of Goods and Services Sold Revenues: Revenues [Abstract] Document Period End Date Document Period End Date Entity Central Index Key Entity Central Index Key Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Unrealized gain (loss) on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Net lease cost Lease, Cost Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Research and development credit, net Deferred Tax Assets, Tax Credit Carryforwards, Research Income Statement Location [Domain] Income Statement Location [Domain] Property, equipment and software, net Property, equipment and software, net Property, Plant and Equipment, Net Property, Equipment and Software Property, Plant and Equipment Disclosure [Text Block] Other non current liabilities Other Liabilities, Noncurrent Other permanent items Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Percentage of common stock share outstanding Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan. Trading Symbol Trading Symbol Maximum employee contribution percent Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent Property, equipment and software Property, Plant and Equipment, Gross Allowance recorded Accounts Receivable, Allowance for Credit Loss Other non current assets Increase (Decrease) in Other Operating Assets Revenues Revenues Janssen Collaboration And License Agreement Janssen Collaboration And License Agreement [Member] Janssen Collaboration And License Agreement Lab equipment Equipment [Member] Vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Inventory, Finished Goods, Gross Inventory, Finished Goods, Gross Weighted average exercise price (in dollars per share) Beginning Balance (in dollars per share) Ending Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Costs and expenses: Costs and Expenses [Abstract] Stock-based compensation expense Share-based Payment Arrangement, Expense Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Cost of Product Sales Cost of Goods and Service [Policy Text Block] Zai Lab Zai Labs [Member] Zai Labs Weighted-average remaining contractual term, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Entity Current Reporting Status Entity Current Reporting Status Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Amortization of premiums and discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Counterparty Name [Axis] Counterparty Name [Axis] Government-sponsored enterprises Government-sponsored enterprises US Government-sponsored Enterprises Debt Securities [Member] Inventory Valuation Reserves Inventory Valuation Reserves Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Balance (in shares) Balance (in shares) Shares, Issued Boehringer Ingelheim International GmbH Boehringer Ingelheim International GmbH [Member] Boehringer Ingelheim International GmbH Sale of common stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in dollars per share) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Debt Securities, Available-for-sale, Allowance for Credit Loss Debt Securities, Available-for-sale, Allowance for Credit Loss Summary of Percentage of Customer Concentration Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Current assets: Assets, Current [Abstract] Provention PRV031 Provention PRV031 [Member] Provention PRV031 Zai Lab Collaboration And License Agreement Zai Lab Collaboration And License Agreement [Member] Zai Lab Collaboration And License Agreement Leases [Abstract] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Deferred revenue Deferred Revenue, Current Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Entity Address, Postal Zip Code Entity Address, Postal Zip Code Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Diluted weighted average number of common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted I-Mab Biopharma Collaboration And License Agreement I-Mab Biopharma Collaboration And License Agreement [Member] I-Mab Biopharma Collaboration And License Agreement Fair Value, Recurring Fair Value, Recurring [Member] Income Taxes Income Tax Disclosure [Text Block] Schedule of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member] Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member] Les Laboratoires Servier And Institut De Recherches Servier (Servier) Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Text Block [Abstract] Text Block [Abstract] Furniture and office equipment Furniture And Office Equipment [Member] Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation. Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Statement of Cash Flows [Abstract] Auditor Firm ID Auditor Firm ID Revenue From Performance Of The Research And Development Activities Revenue From Performance Of The Research And Development Activities [Member] Revenue From Performance Of The Research And Development Activities Discount rate Lessee, Operating Lease, Discount Rate Class of Stock [Line Items] Class of Stock [Line Items] Entity Address, Address Line One Entity Address, Address Line One Net Cash Provided by (Used in) Investing Activities, Total Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value General and administrative General and Administrative Expense [Member] Entity Shell Company Entity Shell Company Expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Employee Stock Employee Stock [Member] Class of Stock [Domain] Class of Stock [Domain] Zai Lab Zai Lab [Member] Zai Lab Impaired assets Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset Money market funds Money Market Funds [Member] Revenues From License Agreements Revenues From License Agreements [Member] Revenues From License Agreements Aggregate intrinsic value, Vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Current Fiscal Year End Date Current Fiscal Year End Date Other non current liabilities Increase (Decrease) in Deferred Rent The increase (decrease) during the reporting period in deferred rent. Provention License Agreement Provention License Agreement [Member] Provention License Agreement Opt-in Fee Opt-in Fee Opt-in Fee Summary of Fair Value Measurement Financial Assets Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Clinical trial activities selling price amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Statement [Table] Statement [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Recently Adopted and Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Other Deferred Tax Assets, Other Unrecognized compensation cost related to non-vested stock-based compensation arrangements Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Range [Axis] Statistical Measurement [Axis] Schedule of Inventory Reserves Schedule of Inventory Reserves [Table Text Block] Schedule of Inventory Reserves Accounts Receivable Accounts Receivable [Policy Text Block] Subsequent Event Subsequent Event [Member] United States federal tax at statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Common Stock, Maximum Amount Available For Issuance, Increase Common Stock, Maximum Amount Available For Issuance, Increase Common Stock, Maximum Amount Available For Issuance, Increase Balance at Beginning of Year Balance at End of Year SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Construction in progress Construction in Progress, Gross Provention Bio, Inc. (Provention) Provention Bio [Member] Provention Bio Inventory Inventory, Policy [Policy Text Block] State net operating loss carryforward Deferred Tax Assets, Operating Loss Carryforwards, State and Local Scenario [Domain] Scenario [Domain] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Stock Incentive Plan 2013 Stock Incentive Plan 2013 [Member] Stock Incentive Plan 2013 [Member] Operating lease cost Operating Lease, Cost Computer equipment Computer Equipment [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Percentage of employee contribution to salary Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Collaboration and Other Agreements [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Weighted-average remaining contractual term, Vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term